#United States #Baltimore #biotech #ETFs #T. Rowe Price

T. Rowe Price Expands ETF Offerings

In a significant move that underscores its commitment to enhance investor choices, T. Rowe Price has unveiled three new active equity exchange-traded funds (ETFs) as of September 17, 2026. This expansion not only reflects T. Rowe Price’s ongoing dedication to innovation in investment management but also provides investors with broadened access to critical market segments. The newly launched funds are the T. Rowe Price Biotech ETF (Ticker: TDNA), T. Rowe Price Small-Cap ETF (Ticker: TSEE), and T. Rowe Price Mid-Cap Equity Research ETF (Ticker: TMID), all of which are now trading on the NASDAQ.

This latest launch marks a noteworthy addition to T. Rowe Price's ETF lineup, which now totals 38 funds, following the introduction of eight new active exchange-traded offerings in 2026 alone. By expanding its portfolio, T. Rowe Price aims to address the evolving needs of investors who are increasingly seeking diversified opportunities within the equity market.

Overview of the New ETFs

1. T. Rowe Price Biotech ETF (TDNA):
This ETF targets long-term capital growth by focusing on biotechnology companies and cutting-edge technologies that have the potential to revolutionize healthcare through innovative treatments and cures. Managed by John Hall, who boasts 11 years of experience within the firm, this ETF plans to maintain a portfolio of approximately 60 to 120 biotech firms. It features a competitive expense ratio of 0.55%, making it an attractive option for investors looking to capitalize on advancements in the biotech sector.

2. T. Rowe Price Small-Cap ETF (TSEE):
This fund is designed to provide investors with a diversified exposure to the U.S. small-cap equity market. Drawing from T. Rowe Price's extensive experience in active small-cap investing, the ETF is supervised by Alex Roik, who is equipped with 13 years of investment experience, including several years at T. Rowe Price. Typically, the Small-Cap ETF consists of more than 200 stocks and comes with an expense ratio of 0.59%.

3. T. Rowe Price Mid-Cap Equity Research ETF (TMID):
This ETF manages an actively constructed U.S. mid-cap strategy, augmenting the firm's established lineup of mutual funds and ETFs. Managed by a team comprising Paige Davis Jr., Amanda Ludwitzke, and Thomas Watson, TMID leverages T. Rowe Price's rigorous research methodologies to filter for the best stock picks among mid-cap companies. It is expected to hold over 300 stocks, with a competitive expense ratio of 0.47%.

Strategic Impact

Tim Coyne, T. Rowe Price’s Global Head of ETFs, emphasized the significance of these new offerings: "TDNA, TSEE, and TMID broaden investors’ access to distinct areas of the market, integrating T. Rowe Price's substantial research capabilities and expertise in active management while capitalizing on the fully transparent ETF structure."

With these additions, T. Rowe Price continues to reinforce its status in the investment management industry. By providing more flexible financial products that are capable of adapting to market changes, the firm empowers both individual and institutional investors to better navigate their financial strategies.

Overall, T. Rowe Price's latest ETF offerings represent a robust growth strategy aimed at diversifying investment choices for clients amidst fluctuating market dynamics. As respected global leaders in asset management, T. Rowe Price remains dedicated to enhancing the client experience through innovative financial solutions and access to evolving market trends.

Conclusion

As investors seek ways to construct diversified portfolios that meet their evolving needs, T. Rowe Price's newly launched ETFs stand as testament to the firm’s proactive approach to market demands. With a continued focus on transparency, efficiency, and expert analysis, these products help ensure that clients are well-equipped for the financial landscape ahead.

For further information on these ETFs and their investment potentials, visit T. Rowe Price.